Mid-term targets within reach; R&D pipeline robust
20/05/19 -"Given the robust oncology, neuroscience and rare disease portfolio, the financial targets for FY22 seem attainable in our view. Somatuline, despite the entry of generics, Dysport, Cabometyx and ..."
Pages
56
Language
English
Published on
20/05/19
You may also be interested by these reports :
10/05/24
Novonesis reported largely in-line Q1 24 numbers. Q1 24 revenue was up 45% on a pro-forma basis, helped by strong performances in the key segments of ...
08/05/24
Sandoz is moving ahead well with two crucial aspects of its medium-term sales and profitability goals: 1/ a strong performance from Biosimilars and ...
07/05/24
Q1 sales missed the consensus estimates, although the CER growth was largely in line with the firm’s full-year outlook. Biosimilars were the main ...
03/05/24
Genmab’s Q1 sales exceeded expectations, although profitability fell somewhat short. This robust performance was led by strong growth across all the ...